ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Order Full text via Infotrieve
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Finnerty, J.
Right arrow Articles by Holgate, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Finnerty, J.
Right arrow Articles by Holgate, S.
Eur Respir J 1992; 5: 323-330
Copyright © ERS Journals Ltd 1992


Clinical Trial

The relative contributions of histamine and prostanoids to bronchoconstriction provoked by isocapnic hyperventilation in asthma

JP Finnerty, A Harvey, and ST Holgate

It has been proposed that exercise provokes bronchoconstriction in asthma by inducing mast cell degranulation, and that this occurs secondary to the hyperpnoea of exercise causing hypertonicity of the airway lining fluid. We investigated the contribution of the mast cell products, histamine and prostaglandins, to the bronchoconstriction induced by isocapnic hyperventilation (ISH) using single doses of terfenadine, a specific histamine H1-receptor antagonist, and flurbiprofen, a potent cyclooxygenase inhibitor. We also investigated the effect of flurbioprofen in single dose on bronchial histamine reactivity. Eleven asthmatics took part in a two phase, double-blind, randomized study. In phase 1, subjects attended on three occasions and received either terfenadine 180 mg, flurbiprofen 150 mg, or placebo, prior to 6 min of ISH. The mean maximum percentage fall in forced expiratory volume in one second (FEV1) induced by ISH was 31.5(+/- 3.2)% following placebo, 29.7(+/- 4.4)% following flurbiprofen (NS), and reduced to 16.6(+/- 3.7)% following terfenadine (p less than 0.01). In phase 2, subjects received bronchial challenge with histamine following either flurbiprofen 150 mg or placebo. No significant change in bronchial reactivity following flurbiprofen was seen. We conclude that as administered in this study, flurbiprofen has no effect on baseline bronchial reactivity to histamine. The inhibitory effect of terfenadine indicates that histamine, probably from airway mast cells, makes an important contribution to bronchoconstriction induced by isocapnic hyperventilation, whereas prostaglandin release has no significant role.


This article has been cited by other articles:


Home page
J. Appl. Physiol.Home page
M. S. Davis, J. R. Malayer, L. Vandeventer, C. M. Royer, E. C. McKenzie, and K. K. Williamson
Cold weather exercise and airway cytokine expression
J Appl Physiol, June 1, 2005; 98(6): 2132 - 2136.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
G.F. Joos and B. O'Connor
Indirect airway challenges
Eur. Respir. J., June 1, 2003; 21(6): 1050 - 1068.
[Abstract] [Full Text] [PDF]


Home page
Br. J. Sports. Med.Home page
S D Anderson, G J Argyros, H Magnussen, and K Holzer
Provocation by eucapnic voluntary hyperpnoea to identify exercise induced bronchoconstriction
Br. J. Sports Med., October 1, 2001; 35(5): 344 - 347.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
O. E. Suman and K. C. Beck
Role of nitric oxide during hyperventilation-induced bronchoconstriction in the guinea pig
J Appl Physiol, April 1, 2001; 90(4): 1474 - 1480.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
O. E. Suman, J. D. Morrow, K. A. O'Malley, and K. C. Beck
Airway function after cyclooxygenase inhibition during hyperpnea-induced bronchoconstriction in guinea pigs
J Appl Physiol, November 1, 2000; 89(5): 1971 - 1978.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the European Respiratory Society.